89 related articles for article (PubMed ID: 14629622)
21. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: effect of formulation and route of immunization on induction of Th1 and Th2 cells.
Conway MA; Madrigal-Estebas L; McClean S; Brayden DJ; Mills KH
Vaccine; 2001 Feb; 19(15-16):1940-50. PubMed ID: 11228364
[TBL] [Abstract][Full Text] [Related]
22. Interaction of the Bordetella pertussis filamentous hemagglutinin with heparin.
Menozzi FD; Gantiez C; Locht C
FEMS Microbiol Lett; 1991 Feb; 78(1):59-64. PubMed ID: 2032624
[TBL] [Abstract][Full Text] [Related]
23. Role of adhesin release for mucosal colonization by a bacterial pathogen.
Coutte L; Alonso S; Reveneau N; Willery E; Quatannens B; Locht C; Jacob-Dubuisson F
J Exp Med; 2003 Mar; 197(6):735-42. PubMed ID: 12629063
[TBL] [Abstract][Full Text] [Related]
24. Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis.
Sato H; Sato Y
Dev Biol Stand; 1985; 61():461-7. PubMed ID: 2872127
[TBL] [Abstract][Full Text] [Related]
25. Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infection.
Alonso S; Pethe K; Mielcarek N; Raze D; Locht C
Infect Immun; 2001 Oct; 69(10):6038-43. PubMed ID: 11553541
[TBL] [Abstract][Full Text] [Related]
26. Prevention of experimental colitis by parenteral administration of a pathogen-derived immunomodulatory molecule.
Braat H; McGuirk P; Ten Kate FJ; Huibregtse I; Dunne PJ; Hommes DW; Van Deventer SJ; Mills KH
Gut; 2007 Mar; 56(3):351-7. PubMed ID: 16952913
[TBL] [Abstract][Full Text] [Related]
27. Cloning and immunologic characterization of a truncated Bordetella bronchiseptica filamentous hemagglutinin fusion protein.
Keil DJ; Burns EH; Kisker WR; Bemis D; Fenwick B
Vaccine; 1999 Dec; 18(9-10):860-7. PubMed ID: 10580199
[TBL] [Abstract][Full Text] [Related]
28. Sulfated glycoconjugate receptors for the Bordetella pertussis adhesin filamentous hemagglutinin (FHA) and mapping of the heparin-binding domain on FHA.
Hannah JH; Menozzi FD; Renauld G; Locht C; Brennan MJ
Infect Immun; 1994 Nov; 62(11):5010-9. PubMed ID: 7927782
[TBL] [Abstract][Full Text] [Related]
29. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
[TBL] [Abstract][Full Text] [Related]
30. Proinflammatory and proapoptotic activities associated with Bordetella pertussis filamentous hemagglutinin.
Abramson T; Kedem H; Relman DA
Infect Immun; 2001 Apr; 69(4):2650-8. PubMed ID: 11254631
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity of a three-component acellular pertussis vaccine administered at birth.
Belloni C; De Silvestri A; Tinelli C; Avanzini MA; Marconi M; Strano F; Rondini G; Chirico G
Pediatrics; 2003 May; 111(5 Pt 1):1042-5. PubMed ID: 12728086
[TBL] [Abstract][Full Text] [Related]
32. Intranasal priming with recombinant Bordetella pertussis for the induction of a systemic immune response against a heterologous antigen.
Mielcarek N; Cornette J; Schacht AM; Pierce RJ; Locht C; Capron A; Riveau G
Infect Immun; 1997 Feb; 65(2):544-50. PubMed ID: 9009311
[TBL] [Abstract][Full Text] [Related]
33. Restricted antibody response to Bordetella pertussis filamentous hemagglutinin induced by whole-cell and acellular pertussis vaccines.
Asgarian-Omran H; Golara M; Abdolmaleki S; Navabi SS; Alipour H; Khoshnoodi J; Hemmati A; Zarei S; Jeddi-Tehrani M; Shokri F
Infect Dis (Lond); 2016 Feb; 48(2):127-32. PubMed ID: 26439274
[TBL] [Abstract][Full Text] [Related]
34. Filamentous hemagglutinin of Bordetella pertussis. A bacterial adhesin formed as a 50-nm monomeric rigid rod based on a 19-residue repeat motif rich in beta strands and turns.
Makhov AM; Hannah JH; Brennan MJ; Trus BL; Kocsis E; Conway JF; Wingfield PT; Simon MN; Steven AC
J Mol Biol; 1994 Aug; 241(1):110-24. PubMed ID: 7519681
[TBL] [Abstract][Full Text] [Related]
35. N-terminal characterization of the Bordetella pertussis filamentous haemagglutinin.
Lambert-Buisine C; Willery E; Locht C; Jacob-Dubuisson F
Mol Microbiol; 1998 Jun; 28(6):1283-93. PubMed ID: 9680216
[TBL] [Abstract][Full Text] [Related]
36. Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine.
Berstad AK; Oftung F; Korsvold GE; Haugen IL; Froholm LO; Holst J; Haneberg B
Vaccine; 2000 May; 18(22):2323-30. PubMed ID: 10738087
[TBL] [Abstract][Full Text] [Related]
37. Beta-helix model for the filamentous haemagglutinin adhesin of Bordetella pertussis and related bacterial secretory proteins.
Kajava AV; Cheng N; Cleaver R; Kessel M; Simon MN; Willery E; Jacob-Dubuisson F; Locht C; Steven AC
Mol Microbiol; 2001 Oct; 42(2):279-92. PubMed ID: 11703654
[TBL] [Abstract][Full Text] [Related]
38. Effects of adsorption of acellular pertussis antigens onto different aluminium salts on the protective activity in an intranasal murine model of Bordetella pertussis infection.
Denoël P; Poolman J; Carletti G; Veitch K
Vaccine; 2002 Jun; 20(19-20):2551-5. PubMed ID: 12057612
[TBL] [Abstract][Full Text] [Related]
39. The filamentous haemagglutinin, a multifaceted adhesion produced by virulent Bordetella spp.
Locht C; Bertin P; Menozzi FD; Renauld G
Mol Microbiol; 1993 Aug; 9(4):653-60. PubMed ID: 8231801
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of Bordetella pertussis filamentous hemagglutinin-mediated cell adherence with monoclonal antibodies.
Leininger E; Probst PG; Brennan MJ; Kenimer JG
FEMS Microbiol Lett; 1993 Jan; 106(1):31-8. PubMed ID: 8440465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
